Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Short term Debt (2025)

Apellis Pharmaceuticals has reported Short term Debt over the past 1 years, most recently at $93.7 million for Q4 2025.

  • Quarterly results put Short term Debt at $93.7 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $93.7 million (changed N/A YoY), and the annual figure for FY2025 was $93.7 million, changed.
  • Short term Debt for Q4 2025 was $93.7 million at Apellis Pharmaceuticals, roughly flat from $93.6 million in the prior quarter.
  • Over the last five years, Short term Debt for APLS hit a ceiling of $93.7 million in Q4 2025 and a floor of $93.6 million in Q3 2025.